Ivermectin: Dr. From Japanese Medical Association Board Won't Rule Out Use of Ivermectin for COVID19

in COVID-193 months ago (edited)

▶️ Watch on 3Speak

During an recent press conference, Dr. Haruo Ozaki - a board member of the Japanese Medical Association - spoke out in support of Ivermectin to be potentially used to treat COVID19 patients in Japan.

In the press conference, Dr. Ozaki states in Japanes, translated into English via subtitles:

“In Africa, if we compare countries distributing Ivermectin once a year with countries which do not give Ivermectin. I mean, they don’t give Ivermectin to prevent Covid, but to prevent parasitic disease, but anyway, if we look at Covid numbers in countries that give Ivermectin, the number of cases is 134.4 per 100,000, and the number of death is 2.2 in 100,000.”

“Now, African countries which do not distribute Ivermectin: 950.6 cases per 100,000 and 29.3 deaths per 100,000,” Ozaki highlighted.

“I believe the difference is clear.”

“Of course, one cannot conclude that Ivermectin is effective only on the basis of these figures, but when we have all these elements, we cannot say that Ivermectin is absolutely not effective, at least not me.”


Ivermectin continues to be controversial, with many doctors and researchers adamant that it is safe and effective for quick treatment of COVID19, while others are not so sure. One thing is clear to me, that the many voices on social media who decry Ivermectin appear to be acting as an ill informed herd who are just parroting the mainstream narrative without really knowing if what they are saying is correct. All too often, commenters ridicule Ivermectin and when pressed are unable to offer any evidence to back up their position beyond “my daughter is a doctor”.

I first posted on Ivermectin back in April and shared various testimony and evidence from experienced pathologists and Doctors who spoke up in favour of it’s use for COVID19. I then posted again several weeks later, a video from Rebel Wisdom which attempted to create a debate on the topic between Doctors/Researchers who were both for and against it’s use. Unfortunately, I do not feel that debate really got to the core of the matter or involved people with sufficient direct experience or evidence to draw concrete conclusions.

It seems that we are getting closer to having a clear understanding regarding Ivermectin for COVID19 and more experts are speaking up in favour of it’s use. I will be focusing more on this topic in coming posts.

Wishing you well,
Ura Soul

Read My User Guide for Hive Here

You Can Vote For Me As A Hive Witness!

Click the big black button below:

ura soul witness vote for hive

View My Witness Application Here

View Some of My Witness Related Posts

Note: Witnesses are the computer servers that run the Hive Blockchain.

Without witnesses there is no Hive blockchain or DApps such as PeakD and 3Speak... You can really help Hive by making your witness votes count!

I am founder of an ethical Digital Marketing Agency called @crucialweb. We help our clients to grow and innovate online and offer discounts for decentralised projects. Get in touch if you'd like to work with us.

I run a Social network for healing, balancing and evolving too. Meet compassionate co-creators of reality, learn, share & make life better!

▶️ 3Speak


2 things Japan and Israel.

The Japan one I suspect this
"It is a covid-19 vaccine "excipient" sold by Sinopeg. The polyethylene glycol PEG listed as an ingredient is sold by Sinopeg." I read somewhere that it claimed to be functional graphene. I cant find it.


COVID VAX VERSIONS It is in there!

Thanks, yes, I was aware of the recall and magnetic reference in Japan, I plan to look into it more when I get time and will maybe make a post on it. I have quite a bit of info here on graphene oxide in relation to the shots, but it will take a lot of time to read through and check out.

The rewards earned on this comment will go directly to the person sharing the post on Twitter as long as they are registered with @poshtoken. Sign up at https://hiveposh.com.